On Tuesday, BMO Capital maintained a positive stance on Eli Lilly (NYSE:LLY) with an Outperform rating and a price target of $1,001.00. The firm's outlook is buoyed by the anticipated approval of donanemab, branded as Kisunla, which is expected to significantly boost revenues for Eli Lilly as well as Biogen/Eisai. The new drug is poised to diversify Eli Lilly's revenue streams, potentially adding up to $7.1 billion at peak sales. This would complement the pharmaceutical giant's existing income from its oncology and incretin franchises.
Kisunla's approval stands out due to its differentiated labeling, which allows for the potential treatment to amyloid negativity. This is in contrast to the chronic treatment schedule associated with Biogen/Eisai's Leqembi. The annual cost for Kisunla is set at $32,000, reflecting its unique position in the market.
Despite the positive outlook, the launch of Kisunla is expected to be gradual, mirroring the slow initial uptake of Leqembi. Nonetheless, the approval of Kisunla marks a significant opportunity for Eli Lilly to expand its presence in the neuroscience sector. The firm anticipates that the presence of two players in the market, Eli Lilly and Biogen/Eisai, is necessary to foster the growth of the required infrastructure to support these treatments.
The forecast for Kisunla's success is part of a broader strategy by Eli Lilly to strengthen its portfolio across various therapeutic areas. With the addition of this new treatment, the company aims to solidify its position in the market and enhance its potential for revenue growth.
In other recent news, Novo Nordisk (NYSE:NVO) has secured approval for its weight-loss medication, Wegovy, in China, marking a significant move in the global market. This development comes amidst a tight timeline due to the impending expiration of its patent on semaglutide, the active ingredient in Wegovy, in less than two years. Despite this, Novo Nordisk's diabetes treatment Ozempic has seen substantial success in China, with sales doubling to approximately $698 million last year.
On the other hand, Eli Lilly has set its Q3 2024 dividend at $1.30 per share. The company also revealed promising results from their phase 3 clinical trials of tirzepatide, showcasing its efficacy in treating moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. Eli Lilly has submitted tirzepatide for the treatment of moderate-to-severe OSA and obesity to the U.S. Food and Drug Administration (FDA), with regulatory action anticipated by the end of the year.
Meanwhile, Barclays has maintained its Overweight rating on Eli Lilly's stock, following the Advisory Committee (AdCom) panel's review of Eli Lilly's Alzheimer's drug, donanemab. The analyst from Barclays projected that donanemab could receive approval within the coming months. These are the recent developments in the pharmaceutical sector.
InvestingPro Insights
As Eli Lilly (NYSE:LLY) gears up for the anticipated approval of Kisunla, the company's stock dynamics present a mixed bag of signals. According to InvestingPro data, Eli Lilly boasts a robust market capitalization of $816.74 billion, underscoring its heavyweight status in the pharmaceutical industry. The company's revenue growth has been impressive, with a 29.76% increase over the last twelve months as of Q1 2024. This growth is in line with the firm's strategic initiatives to diversify and strengthen its portfolio.
InvestingPro Tips highlight Eli Lilly's consistent dividend growth, with a current yield of 0.57% and a significant 15.04% dividend growth in the last twelve months as of Q1 2024. This demonstrates the company's commitment to shareholder returns, having maintained dividend payments for 54 consecutive years. Additionally, Eli Lilly's stock has experienced a remarkable 96.43% return over the past year, which may catch the eye of investors looking for strong performance in their portfolios.
For investors interested in gaining deeper insights into Eli Lilly's financial health and stock performance, InvestingPro offers additional tips that could guide investment decisions. With the use of coupon code PRONEWS24, readers can get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription, unlocking valuable information such as the company's P/E ratio, earnings growth expectations, and stock volatility levels. There are currently 20 additional InvestingPro Tips available for Eli Lilly, providing a comprehensive view of the company's prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.